NCT02171195View on ClinicalTrials.gov

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2000

Primary Completion Date

October 31, 2000

Study Completion Date

October 31, 2000

Conditions
Epilepsy
Interventions
DRUG

BIA 2-093

BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg

DRUG

Placebo

Identical placebo administered as oral tablets with 200 ml potable water.

Trial Locations (1)

SE1 1YR

Guy's Drug Research Unit, London

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02171195 - A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093 | Biotech Hunter | Biotech Hunter